The First Fully AI-Designed Drug Reaches Phase 3 Trials—And Its Maker Is Already Profitable
Insilico Medicine's rentosertib marks a watershed moment for artificial intelligence in pharmaceutical development, advancing to large-scale human testing while the company reports $35.5 million in net profit.
The pharmaceutical industry's AI revolution has reached a critical inflection point. Insilico Medicine has advanced rentosertib—a drug for idiopathic pulmonary fibrosis (IPF)—into Phase 3 clinical trials in China, marking what the company claims is the first fully AI-discovered molecule to reach large-scale human testing. Unlike previous AI-assisted drug candidates, rentosertib emerged from artificial intelligence systems that handled both target identification and molecular design, representing a complete end-to-end AI discovery process.
The milestone arrives alongside an equally significant business achievement: Insilico Medicine reported $35.5 million in net profit for the first half of 2026, demonstrating that AI drug discovery platforms can achieve profitability while their molecules are still in clinical development. The company dosed its first patient in the rentosertib Phase 3 trial on September 10, 2026.
A Pipeline Powered by Partnerships
Insilico Medicine has assembled a portfolio of pharmaceutical partnerships totaling over $5 billion in deal value. Eli Lilly leads with a $2.75 billion agreement, followed by SK Biopharmaceuticals at $2.5 billion, Takeda Pharmaceuticals at $600 million, and China's Qilu Pharmaceutical at $120 million. These collaborations have provided the financial foundation for the company's profitability milestone.
Beyond rentosertib, Insilico's pipeline includes one drug in Phase 2 trials for ulcerative colitis and eight compounds in Phase 1 testing, primarily targeting oncology indications. The company published preliminary data in Nature Biotechnology on September 7, 2026, suggesting that 42 patients treated with rentosertib showed blood biomarker signs of reversed biological age, though these findings require cautious interpretation and further validation.
Co-CEO and Chief Business Officer Alex Zhavoronkov, who assumed his current role in 2025, has positioned the company to capitalize on both AI platform development and drug discovery. The company launched MMAI Gym in January 2026, a service that fine-tunes large language models including GPT, Claude, and Qwen on molecular language, signaling a shift toward AI-as-a-service business models.
China's Regulatory Transformation
Insilico's "China-for-China" strategy leverages improvements in the country's drug regulatory environment. China expanded its drug reviewer corps tenfold after 2015, compressing average review times from 900 days pre-2015 to 300 days by 2019. This acceleration has contributed to record-breaking out-licensing activity, with Chinese deals reaching $136 billion in 2025.
The company also launched LongevityBench on September 17, 2026, a benchmark for testing large language models on aging biology. A study published on the cover of Cell demonstrated that smaller aging-trained models outperformed frontier LLMs, suggesting specialized AI systems may prove more effective than general-purpose models for specific therapeutic areas.
Implications for AI Drug Discovery
Insilico Medicine's Phase 3 advancement raises the bar for the AI drug discovery sector. Competitors must now demonstrate they can match not only the technical achievement of reaching late-stage clinical trials but also the business model sustainability that profitability represents. For healthcare providers, successful completion of rentosertib's Phase 3 trials could expand treatment options for IPF, a condition with limited disease-modifying therapies currently available.
The convergence of clinical progress, profitability, and major pharmaceutical partnerships suggests that AI-discovered drugs are transitioning from experimental concepts to viable commercial products. Whether rentosertib ultimately succeeds in Phase 3 trials will determine if this moment represents a genuine breakthrough or premature celebration.
Sources
Companies in this article
Google Search
Follow Health AI Central on Google
Choose Health AI Central as a preferred source, and Google is more likely to show our reporting in Top Stories.
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.